Microcap Ledger Transcode Therapeutics, Inc. $RNAZ
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 16,930,739 [10-Q 2026-08-14]
What the company doesAI summary of filing
TransCode Therapeutics is a clinical-stage biopharmaceutical company developing immuno-oncology and RNA therapeutics for cancer treatment. The company's lead candidate, TTX-MC138, an antisense inhibitor of microRNA-10b, has completed a Phase 1a clinical trial and is advancing toward Phase 2a development. TransCode generates no revenue and is pre-revenue, funding operations through equity financing and milestone payments. The company's pipeline includes RNA-targeted programs, a cancer vaccine candidate (Seviprotimut-L, acquired via the Polynoma acquisition), and an oncolytic immunotherapy platform (acquired via the Unleash license). [10-K 2026-04-15]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$24.54M | −$10.38M | $8.38M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$34.66M | −$19.52M | $17.81M | [10-K 2026-04-15] |
| FY ended Dec 2024 | — | −$16.75M | −$13.34M | $5.81M | [10-K 2026-04-15] |
- Quarterly cash burn
- −$5.19M
- Cash runway Estimate
- ~4.8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-04-28 | 23,341,336 | [10-K/A 2025-04-30] |
| 2025-05-12 | 23,341,336 | [10-Q 2025-05-14] |
| 2025-08-08 | 833,683 | [10-Q 2025-08-14] |
| 2025-11-10 | 916,968 | [10-Q 2025-11-14] |
| 2026-04-03 | 916,968 | [10-K 2026-04-15] |
| 2026-04-27 | 916,968 | [10-K/A 2026-04-30] |
| 2026-05-12 | 950,302 | [10-Q 2026-05-15] |
| 2026-08-10 | 16,930,739 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2026-05-01; declared effective 2026-05-19 [S-1 2026-05-01]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-22. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-05-22 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-22] |
| 2025-05-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-07] |
| 2024-11-06 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-06] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-03 | Defj, Llc | other | 11,813,859 | — | [4 2026-08-05] |
| 2026-08-03 | Defj, Llc | other | 2,020,582 | — | [4 2026-08-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-01 | 8-K | Material agreement entered; Obligation accelerated |
| 2026-09-28 | 8-K | Other events |
| 2026-09-11 | 8-K | Director or officer change |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-08-03 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-03 | 8-K | Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-07-28 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-28 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-28 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-27 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-23 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-07-20 | 424B3 | Prospectus or prospectus supplement |
Alerts for $RNAZ
Email me when Transcode Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.